secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001104659-24-125505
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma CMO Mina Pastagia departs; separation agreement provides 12-month salary continuation
--------------------------------------------------------------------------------

- Dr. Mina Pastagia terminated as Chief Medical Officer effective Nov 13, 2024; separation agreement executed Dec 2, 2024.
- Agreement provides 12 months of base salary continuation, paid in equal installments starting ~60 days post-termination.
- All unvested stock options and restricted stock units forfeited; vested options must be exercised within 90 days of separation.
- Pastagia releases all claims against the company in exchange for the severance benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924125505/0001104659-24-125505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924125505/tm2430081d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-125505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer